Kristina Laumann

7.1k total citations · 1 hit paper
39 papers, 2.2k citations indexed

About

Kristina Laumann is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Kristina Laumann has authored 39 papers receiving a total of 2.2k indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Hematology, 28 papers in Molecular Biology and 11 papers in Oncology. Recurrent topics in Kristina Laumann's work include Multiple Myeloma Research and Treatments (25 papers), Protein Degradation and Inhibitors (14 papers) and Acute Myeloid Leukemia Research (11 papers). Kristina Laumann is often cited by papers focused on Multiple Myeloma Research and Treatments (25 papers), Protein Degradation and Inhibitors (14 papers) and Acute Myeloid Leukemia Research (11 papers). Kristina Laumann collaborates with scholars based in United States, Canada and Singapore. Kristina Laumann's co-authors include Martha Q. Lacy, Morie A. Gertz, Angela Dispenzieri, Shaji Kumar, S. Vincent Rajkumar, Francis K. Buadi, David Dingli, Suzanne R. Hayman, Stephen J. Russell and John A. Lust and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Kristina Laumann

39 papers receiving 2.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Revised Prognostic Staging System for Light Chain Amyloidosis Incorporating Cardiac Biomarkers and Serum Free Light Chain Measurements

2012 730 citations Shaji Kumar, Angela Dispenzieri et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Kristina Laumann

Since Specialization

Citations

This map shows the geographic impact of Kristina Laumann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kristina Laumann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kristina Laumann more than expected).

Fields of papers citing papers by Kristina Laumann

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kristina Laumann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kristina Laumann. The network helps show where Kristina Laumann may publish in the future.

Co-authorship network of co-authors of Kristina Laumann

This figure shows the co-authorship network connecting the top 25 collaborators of Kristina Laumann. A scholar is included among the top collaborators of Kristina Laumann based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kristina Laumann. Kristina Laumann is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	A Phase II Multicenter Study of the Addition of Azacitidine to Reduced-Intensity Conditioning Allogeneic Transplant for High-Risk Myelodysplasia (and Older Patients with Acute Myeloid Leukemia): Results of CALGB 100801 (Alliance) 2019 ·Biology of Blood and Marrow Transplantation ·Ravi Vij, Jennifer Le‐Rademacher, Kristina Laumann, Vera Hárs, Kouros Owzar, Tsiporah B. Shore, Sumithira Vasu, Amanda F. Cashen, Luis Isola, Thomas C. Shea, Margarida Magalhaes‐Silverman, David D. Hurd, Kenneth R. Meehan, (unknown), Steven M. Devine	23
2	Outcome for pediatric acute promyelocytic leukemia patients at Children's Oncology Group sites on the Leukemia Intergroup Study CALGB 9710 (Alliance) 2018 ·Pediatric Blood & Cancer ·Matthew A. Kutny, Susan Geyer, Kristina Laumann, John Gregory, Cheryl L. Willman, Wendy Stock, Richard A. Larson, Bayard L. Powell, James H. Feusner	14
3	Phase I trial of systemic administration of Edmonston strain of measles virus genetically engineered to express the sodium iodide symporter in patients with recurrent or refractory multiple myeloma 2017 ·Leukemia ·Angela Dispenzieri, Chin Voon Tong, Betsy LaPlant, M. Q. Lacy, Kristina Laumann, David Dingli, Yumei Zhou, Mark J. Federspiel, Morie A. Gertz, S. R. Hayman, Francis K. Buadi, Michael K. O’Connor, Val J. Lowe, K-W Peng, Stephen J. Russell	121
4	A phase 1 trial of 90Y-Zevalin radioimmunotherapy with autologous stem cell transplant for multiple myeloma 2017 ·Bone Marrow Transplantation ·Angela Dispenzieri, Anita D’Souza, Morie A. Gertz, Kristina Laumann, Gregory A. Wiseman, Martha Q. Lacy, Betsy LaPlant, Francis K. Buadi, Suzanne R. Hayman, Shaji Kumar, David Dingli, William J. Hogan, Stephen M. Ansell, D A Gastineau, David J. Inwards, Ivana N. Micallef, Luis F. Porrata, Patrick B. Johnston, Mark R. Litzow, Thomas E. Witzig	9
5	Phase 2 trial of ixazomib in patients with relapsed multiple myeloma not refractory to bortezomib 2015 ·Blood Cancer Journal ·Shaji Kumar, Betsy LaPlant, Vivek Roy, Craig B. Reeder, Martha Q. Lacy, Morie A. Gertz, Kristina Laumann, Melanie Thompson, Thomas E. Witzig, Francis K. Buadi, Candido E. Rivera, Joseph Mıkhael, P. Leif Bergsagel, Prashant Kapoor, Yi L. Hwa, Rafaël Fonseca, A. Keith Stewart, Asher Chanan‐Khan, S. Vincent Rajkumar, Angela Dispenzieri	57
6	Bendamustine, lenalidomide, and dexamethasone (BRD) is highly effective with durable responses in relapsed multiple myeloma 2015 ·American Journal of Hematology ·Shaji Kumar, Amrita Krishnan, Betsy LaPlant, Kristina Laumann, Vivek Roy, Todd M. Zimmerman, Morie A. Gertz, Francis K. Buadi, Keith Stockerl‐Goldstein, (unknown), Mark A. Fiala, (unknown), (unknown), Joan Levy, Ravi Vij	16
7	Arsenic trioxide in front-line therapy of acute promyelocytic leukemia (C9710): prognostic significance of FLT3 mutations and complex karyotype 2013 ·Leukemia & lymphoma ·Xavier Poiré, Barry Kurt Moser, Robert E. Gallagher, Kristina Laumann, Clara D. Bloomfield, Bayard L. Powell, (unknown), (unknown), (unknown), Richard A. Larson, Martin S. Tallman, Frederick R. Appelbaum, Dorie Sher, Cheryl L. Willman, Elisabeth Paietta, Wendy Stock	38
8	The clinical significance of cereblon expression in multiple myeloma 2013 ·Leukemia Research ·Steven R. Schuster, K. Martin Kortuem, Yuan Xiao Zhu, Esteban Braggio, Chang-Xin Shi, Laura A. Bruins, Jessica Schmidt, Greg Ahmann, Shaji Kumar, S. Vincent Rajkumar, Joseph Mıkhael, Betsy LaPlant, Mia D. Champion, Kristina Laumann, Bart Barlogie, Rafaël Fonseca, P. Leif Bergsagel, Martha Q. Lacy, A. Keith Stewart	85
9	Phase 2 trial of intravenously administered plerixafor for stem cell mobilization in patients with multiple myeloma following lenalidomide-based initial therapy 2013 ·Bone Marrow Transplantation ·Shaji Kumar, (unknown), Betsy LaPlant, Martha Q. Lacy, Francis K. Buadi, David Dingli, Morie A. Gertz, Kristina Laumann, (unknown), (unknown), (unknown), Suzanne R. Hayman, Craig B. Reeder, A. Keith Stewart, Angela Dispenzieri, D A Gastineau, Jeffrey L. Winters	17
10	Phase 2 trial of daily, oral polyphenon E in patients with asymptomatic, Rai stage 0 to II chronic lymphocytic leukemia 2012 ·Cancer ·Tait D. Shanafelt, Timothy G. Call, Clive S. Zent, José F. Leis, Betsy LaPlant, Deborah A. Bowen, (unknown), Kristina Laumann, Asish K. Ghosh, Connie Lesnick, Mao‐Jung Lee, Chung S. Yang, Diane F. Jelinek, Charles Erlichman, Neil E. Kay	136
11	FLT3 mutation status is a predictor of early death in pediatric acute promyelocytic leukemia: A report from the Children's Oncology Group 2012 ·Pediatric Blood & Cancer ·Matthew A. Kutny, Barry Kurt Moser, Kristina Laumann, James H. Feusner, Alan S. Gamis, John Gregory, Richard A. Larson, Bayard L. Powell, Wendy Stock, Cheryl L. Willman, William G. Woods, Soheil Meshinchi	38
12	A phase III randomized trial of thalidomide plus zoledronic acid versus zoledronic acid alone in patients with asymptomatic multiple myeloma 2012 ·Leukemia ·Thomas E. Witzig, Kristina Laumann, Martha Q. Lacy, Suzanne R. Hayman, Angela Dispenzieri, Shaji Kumar, Craig B. Reeder, Vivek Roy, John A. Lust, Morie A. Gertz, Philip R. Greipp, Hani Hassoun, Sumithra J. Mandrekar, S. Vincent Rajkumar	70
13	Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for light-chain amyloidosis: long-term results from a phase 2 trial 2012 ·Blood ·Shaji Kumar, Suzanne R. Hayman, Francis K. Buadi, Vivek Roy, Martha Q. Lacy, Morie A. Gertz, Jacob B. Allred, Kristina Laumann, (unknown), David Dingli, Joseph Mıkhael, Craig B. Reeder, A. Keith Stewart, Steven R. Zeldenrust, Philip R. Greipp, John A. Lust, Rafaël Fonseca, Stephen J. Russell, S. Vincent Rajkumar, Angela Dispenzieri	93
14	A comparison of lenalidomide/dexamethasone versus cyclophosphamide/lenalidomide/dexamethasone versus cyclophosphamide/bortezomib/dexamethasone in newly diagnosed multiple myeloma 2011 ·British Journal of Haematology ·(unknown), Craig B. Reeder, Shaji Kumar, M. Q. Lacy, Donna Reece, Angela Dispenzieri, Morie A. Gertz, (unknown), Suzanne R. Hayman, (unknown), David Dingli, John A. Lust, Stephen J. Russell, Kristina Laumann, Joseph Mıkhael, P. Leif Bergsagel, Rafaël Fonseca, S. Vincent Rajkumar, A. Keith Stewart	35
15	Lenalidomide, cyclophosphamide and dexamethasone (CRd) for newly diagnosed multiple myeloma: Results from a phase 2 trial 2011 ·American Journal of Hematology ·Shaji Kumar, Martha Q. Lacy, Suzanne R. Hayman, Keith Stewart, Francis K. Buadi, Jacob B. Allred, Kristina Laumann, Philip R. Greipp, John A. Lust, Morie A. Gertz, Steven R. Zeldenrust, P. Leif Bergsagel, Craig B. Reeder, Thomas E. Witzig, Rafaël Fonseca, Stephen J. Russell, Joseph Mıkhael, David Dingli, S. Vincent Rajkumar, Angela Dispenzieri	44
16	Phase II study of the histone deacetylase inhibitor belinostat (PXD101) for the treatment of myelodysplastic syndrome (MDS) 2011 ·Annals of Hematology ·Amanda F. Cashen, Mark Juckett, (unknown), Mark R. Litzow, Patrick J. Flynn, John R. Eckardt, Betsy LaPlant, Kristina Laumann, Charles Erlichman, John F. DiPersio	53
17	Phase I Trial of a Novel Combination of An HDAC Inhibitor (LBH589) and An mTOR Inhibitor (RAD001) in Lymphoid and Plasma Cell Malignancies 2011 ·Blood ·Shaji Kumar, Joseph Mıkhael, Betsy LaPlant, Joseph P. Colgan, David J. Inwards, Patrick B. Johnston, Kristina Laumann, Ivana N. Micallef, Grzegorz S. Nowakowski, Stephen M. Ansell, Kelly K. Curtis, Angela Dispenzieri, Martha Q. Lacy, José F. Leis, Donald W. Northfelt, Craig B. Reeder, James L. Slack, Thomas E. Witzig	4
18	Phase II trials of single-agent anti-VEGF therapy for patients with chronic lymphocytic leukemia 2010 ·Leukemia & lymphoma ·Tait D. Shanafelt, Clive S. Zent, John C. Byrd, Charles Erlichman, Betsy LaPlant, Asish K. Ghosh, Timothy G. Call, Miguel A. Villalona‐Calero, Diane F. Jelinek, Deborah A. Bowen, Kristina Laumann, Wenting Wu, Curtis A. Hanson, Neil E. Kay	25
19	Lendalidomide Consolidation After First-Line Chemoimmunotherapy for Patients with Previously Untreated CLL 2010 ·Blood ·Tait D. Shanafelt, Han W. Tun, Curtis A. Hanson, Clive S. Zent, José F. Leis, Timothy G. Call, Betsy LaPlant, Deborah A. Bowen, Kristina Laumann, Diane F. Jelinek, Neil E. Kay	4
20	Pomalidomide (CC4047) Plus Low-Dose Dexamethasone As Therapy for Relapsed Multiple Myeloma 2009 ·Journal of Clinical Oncology ·Martha Q. Lacy, Suzanne R. Hayman, Morie A. Gertz, Angela Dispenzieri, Francis K. Buadi, Shaji Kumar, Philip R. Greipp, John A. Lust, Stephen J. Russell, David Dingli, Robert A. Kyle, Rafaël Fonseca, P. Leif Bergsagel, Vivek Roy, Joseph Mıkhael, A. Keith Stewart, Kristina Laumann, Jacob B. Allred, Sumithra J. Mandrekar, S. Vincent Rajkumar	226

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL

2026

Contact